Research Breakthrough: Researchers at the University of Texas MD Anderson Cancer Center identified key gene changes in certain mucinous ovarian cancers with potential to guide care and predict outcomes when identified through genetic testing at diagnosis. Mucinous ovarian cancer is a rare type of ovarian cancer that behaves differently from more common forms, and doctors … Continued
Research Breakthrough: At The University of Chicago, researchers systematically tested existing therapies to find an effective drug combination that shows promise as a treatment for ovarian cancer. Scientists are looking for better ways to treat high-grade serous ovarian cancer, especially the cancer cells that survive standard chemotherapy (carboplatin) and lead to recurrence. In this study, researchers … Continued
The Food and Drug Administration has granted accelerated approval to Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets), made by Verastem Oncology, making it the first FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC) who have a KRAS mutation. The approval is based on the results of the Phase 2 RAMP 201 clinical … Continued
Research Breakthrough: A team of researchers at The University of Texas Health Science Center developed a pioneering AI tool to better predict treatment response, a step toward earlier personalized treatment plans. The researchers created a new artificial intelligence tool that uses images from diagnostic laparoscopy, minimally invasive camera-made images taken inside the abdomen, to predict how patients … Continued
Ovarian Cancer Research Alliance is proud to support five outstanding scientists through our Early Career Investigator Grants, part of the $6 million in new research OCRA is funding in 2025. These grants are essential to ensure that promising researchers with an established commitment to ovarian and related gynecologic cancers can continue to focus their efforts on … Continued
Research Breakthrough: Scientists at The University of Texas MD Anderson Cancer Center uncovered key differences in immune environments between primary tumors and metastases that may explain why high-grade serous ovarian carcinoma often suppresses the immune system. High-grade serous ovarian carcinoma (HGSC) tumors are often able to suppress the immune system to evade being detected and … Continued
OCRA is proud to announce the first three recipients of the $6 million we have awarded to support groundbreaking ovarian and related gynecologic cancer research in 2025. And we’re not stopping there—stay tuned as we continue to expand our investment in research this year. This is the first in a multi-part series introducing our newest … Continued
Rates of cervical precancer dropped nearly 80% between 2008 and 2022 among screened women aged 20 to 24, according to the latest Morbidity and Mortality Weekly Report from Centers for Disease Control and Prevention (CDC). The report notes that women in this age group are those most likely to have received the HPV vaccine. Read the … Continued
Ovarian Cancer Research Alliance (OCRA), the largest global organization dedicated to advancing ovarian and related gynecologic cancer research, announced today the recipients of two prizes awarded for noteworthy work in the field of ovarian cancer research. One honoree received the 2024 Rosalind Franklin Prize for Excellence in Ovarian Cancer Research in recognition of his groundbreaking … Continued
OCRA Joins Forces With Rivkin Center for Ovarian Cancer Research Ovarian Cancer Research Alliance (OCRA) has announced that the Rivkin Center for Ovarian Cancer Research will join with OCRA effective April 1, 2025. This historic collaboration unites two respected organizations committed to advancing research for a cure for ovarian and all gynecologic cancers. “OCRA has always … Continued
In a new interview with journalist Marcel Clarke for Clarke’s Closer Look, OCRA grantee Dr. Daniel Heller of Memorial Sloan Kettering Cancer Center discusses how his lab is utilizing artificial intelligence (AI) to develop a cutting-edge blood test to detect ovarian cancer at its earliest stages. This OCRA-funded study is in partnership with Microsoft AI … Continued
A study recently published in Science Advances and supported in part by Ovarian Cancer Research Alliance has advanced scientists’ understanding of how to potentially overcome immune evasion in ovarian cancer. The research team involved current and former Memorial Sloan Kettering Cancer Center researchers, including OCRA grantee Melica Brodeur MD, MSc, now at McGill University, who … Continued
Get email updates about research news, action alerts, and ways to join the fight.
